Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

NCT05245500 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT05245500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Recruiting
Start date
June 9, 2022
Completion date
December 10, 2027
Enrollment
336 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, malignant peripheral nerve sheath tumors, mesothelioma, non small cell lung cancer, pancreatic adenocarcinoma, solid tumor